AC Immune: 2019 financial results and R&D outlook

Ongoing strong financial position with CHF 288.6 million in cash, ensuring the Company is fully financed through Q1 2024, excluding potential incoming milestones
Received CHF 110 million in upfront and development milestone payments and a USD 50 million equity note in 2019 as a result of the Morphomer Tau Lilly partnership
Added new potential CHF 60 million Phase 2 initiation milestone and achieved CHF 10 million milestone in Q1 2020 in Lilly partnership
Five clinical milestones expected in 2020 including the first Phase 2 readout of an anti-Tau antibody in Alzheimer’s disease (AD)
Initiated three clinical trials targeting Tau and a substudy within the ongoing Phase 2 Alzheimer’s Prevention Initiative trial

You may also be interested in

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, today announces that the first subjects have been dosed in its first-in-human clinical trial of its lead Central Nervous System (CNS) compound VNA-318. Readout of this combined single and multiple ascending dose trial is expected in the summer of 2025.
December 18, 2024

BioCopy CEO Matthias Wiedenfels honored as winner of "Germany's 30 by 2030" award.
December 17, 2024

MedScienceSwiss is developing a non-pharmaceutical therapy for the treatment of antibiotic-resistant bacteria. The goal: to significantly reduce the number of deaths in hospitals due to nosocomial (difficult-to-treat) infections. The technology is not only intended to serve as an alternative to the current plan A (antibiotics), but also to function as a general approach to the treatment of resista
December 3, 2024